| 36 |
Oral Abstracts (Session 5 of 5)
|
Moderator: David Keast, MSc, MD, CCFP, FCFP (Presentation 36.3) A randomized, multicenter, clinical trial of a biocellulose wound dressing (BWD) for the treatment of chronic venous ulcers Oscar M. Alvarez, PhD, Center for Palliative Wound Care, Calvary Hospital, Bronx, NY; James Menzoian, MD, Department of Surgery, Boston University, Boston, Mass; Marie Brown Etris, RN, CWOCN, Etris Associates, Philadelphia, Pa; Tania Phillips, MD, Department of Dermatology, Boston University, Boston, Mass Objectives: The objective of the trial was to test the safety and efficacy of a novel wound dressing (BWD) produced from microbial cellulose (Acetobacter xylinium) in the treatment of venous ulcers. Design: The trial was a prospective, randomized study. Setting: This multicenter study was performed in the outpatient setting. Intervention: Each patient with a venous ulcer received either standard care (nonadherent dressing plus compression therapy) or BWD plus compression therapy. Wounds were evaluated for autolytic debridement, pain, healing rate, time to complete granulation, and time to closure. Outcomes: The study was completed as planned in 49 randomized patients. Results: Treatment with BWD plus compression was more effective than standard care in autolytic debridement (83% vs. 26%; p=0.0001); wound pain (75% of the patients treated with BWD reported no pain compared to 36% in the standard care group; p=0.0391); time to complete granulation (25 days vs. 36 days; p=0.268); and percent reduction in wound area (74% vs. 49%; p=0.322). Conclusions: Autolytic debridement was significantly greater in the BWD-treated group leading to exposed wound margins and cleaner wound beds. The BWD-treated group reported significantly less wound pain than the group treated with standard care. The time to granulation was 69.4% less, and the rate of wound healing was 66.2% greater in the BWD treated group. |
|